Literature DB >> 16634742

Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time.

G Hron1, S Eichinger, A Weltermann, P Quehenberger, W M Halbmayer, P A Kyrle.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) is a multi-factorial disease. Extensive thrombophilia screening is costly and often inconclusive. Simple laboratory methods are required to predict the risk of recurrence.
OBJECTIVE: To assess if measurement of activated partial thromboplastin time (APTT) allows stratification of patients with VTE into high- and low-risk categories with regard to recurrence. PATIENTS AND METHODS: We prospectively followed 918 patients with a first unprovoked VTE and studied the relationship between recurrence and an APTT after discontinuation of anticoagulation. APTT was expressed as a ratio of test to reference coagulation times. Study endpoint was symptomatic recurrent VTE.
RESULTS: Venous thromboembolism recurred in 101 (11%) patients. Patients without recurrence had a greater APTT ratio than those with recurrence (0.97 +/- 0.09 vs. 0.93 +/- 0.09, P = 0.001). After 4 years, probability of recurrent VTE was 8.5% (95% CI: 5.5-11.5%) among patients with a ratio equal to or > 0.95 and 15.6% (95% CI: 11.4-19.9%) among patients with a lower ratio (P = 0.005). Compared with patients with an APTT ratio < 0.95, the relative risk (RR) of recurrence among patients with a ratio equal to or > 0.95 was 0.56 (95% CI: 0.38-0.84, P = 0.005) before and 0.58 (95% CI: 0.39-0.87, P = 0.009) after adjustment for sex, age, factor V Leiden, and factor II G20210A.
CONCLUSIONS: Measurement of APTT allows stratification of patients with VTE into high- and low-risk categories with regard to recurrence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634742     DOI: 10.1111/j.1538-7836.2006.01868.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

1.  Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.

Authors:  Weihong Tang; Christine Schwienbacher; Lorna M Lopez; Yoav Ben-Shlomo; Tiphaine Oudot-Mellakh; Andrew D Johnson; Nilesh J Samani; Saonli Basu; Martin Gögele; Gail Davies; Gordon D O Lowe; David-Alexandre Tregouet; Adrian Tan; James S Pankow; Albert Tenesa; Daniel Levy; Claudia B Volpato; Ann Rumley; Alan J Gow; Cosetta Minelli; John W G Yarnell; David J Porteous; John M Starr; John Gallacher; Eric Boerwinkle; Peter M Visscher; Peter P Pramstaller; Mary Cushman; Valur Emilsson; Andrew S Plump; Nena Matijevic; Pierre-Emmanuel Morange; Ian J Deary; Andrew A Hicks; Aaron R Folsom
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

Review 2.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

3.  Activated partial thromboplastin time and risk of future venous thromboembolism.

Authors:  Neil A Zakai; Tetsuya Ohira; Richard White; Aaron R Folsom; Mary Cushman
Journal:  Am J Med       Date:  2008-03       Impact factor: 4.965

Review 4.  Predicting the risk of venous thromboembolism recurrence.

Authors:  John A Heit
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

Review 5.  Guidance for the treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Michael B Streiff; Giancarlo Agnelli; Jean M Connors; Mark Crowther; Sabine Eichinger; Renato Lopes; Robert D McBane; Stephan Moll; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

6.  A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study.

Authors:  Lu-Chen Weng; Mary Cushman; James S Pankow; Saonli Basu; Eric Boerwinkle; Aaron R Folsom; Weihong Tang
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

Review 7.  Epidemiology and risk factors for venous thrombosis.

Authors:  Mary Cushman
Journal:  Semin Hematol       Date:  2007-04       Impact factor: 3.851

8.  Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Gian Luca Salvagno; Gian Cesare Guidi; Emmanuel J Favaloro
Journal:  J Thromb Thrombolysis       Date:  2008-09-12       Impact factor: 2.300

9.  Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma.

Authors:  Armando Tripodi; Maria Domenica Cappellini; Veena Chantarangkul; Lidia Padovan; Maria Rosaria Fasulo; Alessia Marcon; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2009-07-31       Impact factor: 9.941

Review 10.  Optimal duration of anticoagulation in patients with venous thromboembolism.

Authors:  Paolo Prandoni; Chiara Piovella; Luca Spiezia; Fabio Dalla Valle; Raffaele Pesavento
Journal:  Indian J Med Res       Date:  2011-07       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.